---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-077374"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T10:45:28.379672+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome settles SUNOSI patent litigation with Hetero; generic entry delayed until 2040

## Summary
- Settlement resolves patent litigation with Hetero over generic version of SUNOSI (solriamfetol).
- Hetero licensed to sell generic SUNOSI on or after Sept 1, 2040 (if pediatric exclusivity) or March 1, 2040.
- Settlement agreement subject to review by FTC and DOJ.
- Similar patent litigation against other SUNOSI generic applicants remains pending in New Jersey court.

## SEC filing metadata
- accession: 0000950170-25-077374
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025077374/0000950170-25-077374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025077374/axsm-20250527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-077374
- JSON: https://secwatch.observer/filing/0000950170-25-077374.json
- Plain text: https://secwatch.observer/filing/0000950170-25-077374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.